2023
DOI: 10.26434/chemrxiv-2023-ltv7l
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Rational design of highly potent SARS-CoV-2 nsp14 methyltransferase inhibitors

Abstract: The search for new drugs against COVID-19 and its causative agent, SARS-CoV-2, is one of the major trends in current medicinal chemistry. Targeting capping machinery could be one of therapeutic concepts based on a unique mechanism of action. Viral RNA cap synthesis involves two methylation steps, the first of which is mediated by the nsp14 protein. Here, we rationally designed and synthesized a series of compounds capable of binding to both the S-adenosyl-L-methionine and the RNA binding site of SARS-CoV-2 nsp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 24 publications
0
3
0
Order By: Relevance
“…5,[10][11][12][13][14] Spurred by the recent SARS-CoV-2 pandemic, the N7-MTase nsp14 is an emerging target of great interest for inhibitor development, and over the past three years numerous groups worldwide have proposed original active compounds against this enzyme. 15-28 Most nsp14 inhibitors have been designed as SAM-derived compounds, 17,19,21,[23][24][25][26]28 but highthroughput screening of large libraries 18,20 or a structure-based docking approach on large libraries 27 have also lead to non-SAM-like inhibitors of nsp14. In the latest docking study, 27 the most potent inhibitors are low micromolar, much weaker than the most potent SAM-derived inhibitor, which is active in the subnanomolar range against SARS-CoV-2 nsp14.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…5,[10][11][12][13][14] Spurred by the recent SARS-CoV-2 pandemic, the N7-MTase nsp14 is an emerging target of great interest for inhibitor development, and over the past three years numerous groups worldwide have proposed original active compounds against this enzyme. 15-28 Most nsp14 inhibitors have been designed as SAM-derived compounds, 17,19,21,[23][24][25][26]28 but highthroughput screening of large libraries 18,20 or a structure-based docking approach on large libraries 27 have also lead to non-SAM-like inhibitors of nsp14. In the latest docking study, 27 the most potent inhibitors are low micromolar, much weaker than the most potent SAM-derived inhibitor, which is active in the subnanomolar range against SARS-CoV-2 nsp14.…”
Section: Introductionmentioning
confidence: 99%
“…23,26 N-Arylsulfonamides, known to be ubiquitous functional scaffolds among medicinally interesting molecules, proved to be here a key component in explaining the inhibitors' high affinity for SARS-CoV-2 nsp14 (tens of nanomolar inhibition) in our work 23,26,29 and that of others. 24,28 In these potent inhibitors, the N-arylsulfonamide moieties were directly attached to the C5′ ribose atom of adenosine or its derivatives (Fig. 1A).…”
Section: Introductionmentioning
confidence: 99%
“…It is of interest to note that prior approaches targeting this protein have typically combined synthesis with docking strategies to rene and enhance the potency of existing inhibitors. 14,15 In contrast, our approach exploits the power of virtual screening across various levels of accuracy, alongside the use of the NCI open compound collection 16,17 -a database encompassing over 250 000 molecules freely available to researchers worldwide. For an overview of the property distributions within this collection, refer to Fig.…”
Section: Introductionmentioning
confidence: 99%